Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy - Trial NCT05949333
Access comprehensive clinical trial information for NCT05949333 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eunseong Medical Foundation Good GANG-AN HOSPITAL and is currently Not yet recruiting. The study focuses on Breast Neoplasms. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Timeline & Enrollment
Phase 4
Aug 01, 2023
Jan 01, 2025
Primary Outcome
Incidence rate of severe neutropenia Incidence rate of severe neutropenia
Summary
Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first
 round are randomly assigned to either the control or experimental arm. Patients in the
 control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm
 will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim
 administration date from day 1 to day 3 starting from the second round of chemotherapy could
 reduce the incidence of neutropenia
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05949333
Non-Device Trial